Matches in SemOpenAlex for { <https://semopenalex.org/work/W1569667912> ?p ?o ?g. }
- W1569667912 endingPage "9" @default.
- W1569667912 startingPage "1" @default.
- W1569667912 abstract "Endothelial dysfunction is the initial pathophysiological step in a progression of vascular damage that leads to overt cardiovascular and chronic kidney disease. Angiotensin II, the primary agent of the renin-angiotensin system (RAS), has a central role in endothelial dysfunction. Therefore, RAS blockade with an angiotensin receptor blocker (ARB) and/or angiotensin-converting enzyme (ACE) inhibitor provides a rational approach to reverse endothelial dysfunction, reduce microalbuminuria, and, thus, improves cardiovascular and renal prognosis. ARBs and ACE inhibitors act at different points in the RAS pathway and recent evidence suggests that there are differences regarding their effects on endothelial dysfunction. In addition to blood pressure lowering, studies have shown that ARBs reduce target-organ damage, including improvements in endothelial dysfunction, arterial stiffness, the progression of renal dysfunction in patients with type 2 diabetes, proteinuria, and left ventricular hypertrophy. The ONgoing Telmisartan Alone in combination with Ramipril Global Endpoint Trial (ONTARGET) Programme is expected to provide the ultimate evidence of whether improved endothelial function translates into reduced cardiovascular and renal events in high-risk patients, and to assess possible differential outcomes with telmisartan, the ACE inhibitor ramipril, or a combination of both (dual RAS blockade). Completion of ONTARGET is expected in 2008." @default.
- W1569667912 created "2016-06-24" @default.
- W1569667912 creator A5007735183 @default.
- W1569667912 creator A5040062593 @default.
- W1569667912 creator A5049235067 @default.
- W1569667912 date "2007-01-01" @default.
- W1569667912 modified "2023-10-12" @default.
- W1569667912 title "Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme." @default.
- W1569667912 cites W1518058648 @default.
- W1569667912 cites W1534568702 @default.
- W1569667912 cites W180946569 @default.
- W1569667912 cites W1966650684 @default.
- W1569667912 cites W1978581565 @default.
- W1569667912 cites W1984061204 @default.
- W1569667912 cites W1984860118 @default.
- W1569667912 cites W1987345892 @default.
- W1569667912 cites W1988742278 @default.
- W1569667912 cites W1993378083 @default.
- W1569667912 cites W2006777248 @default.
- W1569667912 cites W2011396117 @default.
- W1569667912 cites W2016654529 @default.
- W1569667912 cites W2019546349 @default.
- W1569667912 cites W2031053334 @default.
- W1569667912 cites W2031614618 @default.
- W1569667912 cites W2033199439 @default.
- W1569667912 cites W2039406779 @default.
- W1569667912 cites W2041401793 @default.
- W1569667912 cites W2044773944 @default.
- W1569667912 cites W2048635427 @default.
- W1569667912 cites W2056976690 @default.
- W1569667912 cites W2057116025 @default.
- W1569667912 cites W2063217857 @default.
- W1569667912 cites W2063506869 @default.
- W1569667912 cites W2075675369 @default.
- W1569667912 cites W2076629029 @default.
- W1569667912 cites W2077080091 @default.
- W1569667912 cites W2081938413 @default.
- W1569667912 cites W2082069148 @default.
- W1569667912 cites W2083481797 @default.
- W1569667912 cites W2089549133 @default.
- W1569667912 cites W2095032062 @default.
- W1569667912 cites W2096965805 @default.
- W1569667912 cites W2102723961 @default.
- W1569667912 cites W2106727620 @default.
- W1569667912 cites W2107031719 @default.
- W1569667912 cites W2110062302 @default.
- W1569667912 cites W2110160119 @default.
- W1569667912 cites W2110182057 @default.
- W1569667912 cites W2110663794 @default.
- W1569667912 cites W2118286022 @default.
- W1569667912 cites W2119869567 @default.
- W1569667912 cites W2123391323 @default.
- W1569667912 cites W2123831918 @default.
- W1569667912 cites W2125943457 @default.
- W1569667912 cites W2133694559 @default.
- W1569667912 cites W2134899427 @default.
- W1569667912 cites W2137256594 @default.
- W1569667912 cites W2140106465 @default.
- W1569667912 cites W2151100203 @default.
- W1569667912 cites W2155336724 @default.
- W1569667912 cites W2155766891 @default.
- W1569667912 cites W2159729565 @default.
- W1569667912 cites W2160021677 @default.
- W1569667912 cites W2160280522 @default.
- W1569667912 cites W2162010936 @default.
- W1569667912 cites W2170477112 @default.
- W1569667912 cites W2309975949 @default.
- W1569667912 cites W2341645956 @default.
- W1569667912 cites W2396772514 @default.
- W1569667912 cites W2475261460 @default.
- W1569667912 cites W2613483874 @default.
- W1569667912 cites W2972550292 @default.
- W1569667912 cites W3021250193 @default.
- W1569667912 cites W4255882085 @default.
- W1569667912 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1994043" @default.
- W1569667912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17583170" @default.
- W1569667912 hasPublicationYear "2007" @default.
- W1569667912 type Work @default.
- W1569667912 sameAs 1569667912 @default.
- W1569667912 citedByCount "15" @default.
- W1569667912 countsByYear W15696679122012 @default.
- W1569667912 countsByYear W15696679122014 @default.
- W1569667912 countsByYear W15696679122015 @default.
- W1569667912 countsByYear W15696679122016 @default.
- W1569667912 countsByYear W15696679122019 @default.
- W1569667912 countsByYear W15696679122022 @default.
- W1569667912 countsByYear W15696679122023 @default.
- W1569667912 crossrefType "journal-article" @default.
- W1569667912 hasAuthorship W1569667912A5007735183 @default.
- W1569667912 hasAuthorship W1569667912A5040062593 @default.
- W1569667912 hasAuthorship W1569667912A5049235067 @default.
- W1569667912 hasConcept C104849204 @default.
- W1569667912 hasConcept C126322002 @default.
- W1569667912 hasConcept C134018914 @default.
- W1569667912 hasConcept C159641895 @default.
- W1569667912 hasConcept C164705383 @default.
- W1569667912 hasConcept C203092338 @default.
- W1569667912 hasConcept C27016395 @default.